News summarySEC EDGARNov 4, 2026, 12:00 PM
Relay Therapeutics, 8-K (2.02, 9.01): reported results of operations
Relay Therapeutics reported third-quarter 2026 results, with approximately $849 million in cash, cash equivalents and investments, projected mid-2027 enrollment completion for its Phase 3 breast cancer trial, and updates on vascular-anomaly programs and commercial preparations.